|
A Holiday Season Note from the CEO
|
1
|
BIOASIS TECHNOLOGIES INC
|
Jan 04, 2016 07:13AM
|
|
A hunch about the below median LDL-C observation
|
12
|
Resverlogix Corp.
|
Nov 20, 2019 01:58PM
|
|
A lesson on futility analyses from the CETP inhibitors
|
6
|
Resverlogix Corp.
|
May 10, 2017 02:47PM
|
|
A New Frontier in CV Risk Reduction for Patients With Type 2 Diabetes
|
5
|
Resverlogix Corp.
|
Dec 17, 2018 10:02AM
|
|
A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms
|
8
|
Resverlogix Corp.
|
Oct 26, 2020 08:15AM
|
|
AACR 2018
|
2
|
Zenith Epigenetics
|
Jan 18, 2018 04:07PM
|
|
AACR 2019
|
4
|
Zenith Epigenetics
|
Feb 27, 2019 10:45PM
|
|
AACR 2020 Poster
|
7
|
Zenith Epigenetics
|
Jun 29, 2020 07:21AM
|
|
AACR April 24-29, 2020 for some Zenith Clinical Trial Results?
|
7
|
Zenith Epigenetics
|
Feb 20, 2020 02:24PM
|
|
AAIC and MD&A
|
4
|
Resverlogix Corp.
|
Jul 23, 2018 09:30AM
|
|
AAIC poster
|
2
|
Resverlogix Corp.
|
Jul 14, 2019 02:36PM
|
|
AAIC presentation in July
|
4
|
Resverlogix Corp.
|
Jun 19, 2018 12:06PM
|
|
ABCA1 overexpression worsens colorectal cancer prognosis and this can be ameliorated by apabetalone
|
7
|
Resverlogix Corp.
|
Aug 14, 2018 09:11AM
|
|
Abstract for American Diabetes Association presentation June 11, 2016
|
6
|
Resverlogix Corp.
|
Jun 05, 2016 05:34PM
|
|
ACC 2018 Late Breakers Announce
|
7
|
Resverlogix Corp.
|
Jan 23, 2018 03:30PM
|
|
ACC 2019 Abstracts
|
5
|
Resverlogix Corp.
|
Mar 04, 2019 11:58AM
|
|
ACC 2019?
|
3
|
Resverlogix Corp.
|
Nov 19, 2018 04:45PM
|
|
ACC abstracts are out
|
5
|
Resverlogix Corp.
|
Mar 06, 2017 10:57PM
|
|
ACC/WCC 2020
|
8
|
Resverlogix Corp.
|
Dec 25, 2019 06:34PM
|
|
ACC/WCC Virtual 2020
|
5
|
Resverlogix Corp.
|
Mar 27, 2020 11:07PM
|
